Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to chemotherapy, with or without bevacizumab, significantly improved PFS and OS ...
Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy following chemoradiation did not prolong OS or PFS compared with chemoradiation alone ...
HONG KONG, March 4, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results